OSD
Strategies for ensuring a consistent, inspection-ready supply of highly potent products
Highly potent active pharmaceutical ingredients (HPAPIs) are becoming increasingly integral in the treatment of cancers and immunological diseases.
To meet rising demand for highly potent therapeutics and ensure their timely delivery to patients, pharmaceutical companies need to establish a reliable and consistent supply of HPAPIs. This can be challenging due to the high standards required to safely handle highly active compounds, both to minimise cross-contamination risk and protect on-site workers.
As a result, manufacturers need to consider their strategies for maintaining supply that aligns with strict regulatory requirements.
The technical challenges of HPAPI manufacturing
As demand for HPAPIs grows, drug developers are increasingly partnering with contract development and manufacturing organisations (CDMOs) to meet their supply requirements. This requires a very specific type of partner, one that can offer the sophisticated containment systems and quality frameworks necessary to meet the exacting requirements of HPAPI manufacture.
HPAPIs (those with an occupational exposure limit (OEL) below 10μg/m³ over an eight-hour average time period) require strict controls to protect against cross-contamination during low-OEL work. They also necessitate risk assessments that prevent air, surface, worker and equipment contamination. These standards are mandated by global regulatory frameworks, including U.S. and European current good manufacturing practice (cGMP) guidelines, ICH risk-management principles and recommendations for ISPE guidance.
Consequently, HPAPI manufacturers must carefully and strategically plan their process and facility design to ensure that production takes place safely and consistently, particularly as batch sizes increase.
Maintaining consistency as volumes increase
As production volumes rise, maintaining consistent HPAPI manufacturing becomes more challenging. Scale-up can place pressure on multiple parts of the process, including:
- HVAC and filtration systems, which must continue to support reliable containment at higher throughput
- Process performance, where shifts in blend uniformity or granule density can affect product consistency
- Cleaning validation, which often becomes more complex as equipment grows in size and design
- Sampling requirements, which may increase to confirm compliance at commercial scale
- Project timelines, which can come under strain if issues emerge during scale-up
If these factors are not managed effectively, the result can be delays, batch loss and added cost.
How Recipharm delivers strategies for uninterrupted compliant supply
A trusted partner must be able to guarantee a reliable and timely supply of HPAPIs while aligning with increasingly stringent regulatory standards.
They also need to demonstrate the flexibility and commercial capacity to scale effectively.
Recipharm supports HPAPI development and manufacturing with several strategies that ensure compliance and supply reliability:
Specialised high potency programmes
As an HPAPI specialist, we use purpose-built high-containment facilities to guarantee that HPAPI manufacture progresses without the need for compromise or adaptation.
Our systems are engineered for low-OEL work at every stage, with closed transfer methods that prevent product loss and exposure risk.
Integrated quality control
Our quality control processes are designed to safely manage potent materials. We use sterile access system (SAS) equipped rooms that protect both samples and personnel from contamination.
We also lay out rigorous pathways for the handling of samples to ensure containment, and align cleaning requirements with the toxicological profile of each API.
Aligned frameworks for transfer and scale-up
When teams are fragmented, delays and communication issues can occur, leading to optimisation issues and strategic uncertainty.
We offer end-to-end support from development to manufacturing, helping to streamline transfer activities and giving developers access to expert support at each stage of the process.
We help establish your requirements early, and use statistical modelling and simulation tools such as our own ReciPredict™ platform to provide greater process transparency during scale-up.
With a clearer understanding of the entire product lifecycle, we can deliver more consistent products that meet regulatory requirements and strengthen supply reliability.
Trustworthiness is a vital component of any partner relationship, particularly when production demands are high. At Recipharm, we offer tested and effective HPAPI production strategies that perform at scale and under tight timelines, with 95% right-first-time and 93% on time delivery.
Looking for a partner to deliver on your HPAPI requirements?
Read our white paper to learn more about how Recipharm can help deliver scalable, consistent supply.